Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma

The oral proteasome inhibitor ixazomib is approved in the United States, European Union and other countries, in combination with oral lenalidomide and dexamethasone (Rd), for the treatment of patients with multiple myeloma who have received at least one prior therapy. Approval was based on the globa...

Descripción completa

Detalles Bibliográficos
Autores principales: Kumar, Shaji, Moreau, Philippe, Hari, Parameswaran, Mateos, Maria‐Victoria, Ludwig, Heinz, Shustik, Chaim, Masszi, Tamas, Spencer, Andrew, Hájek, Roman, Romeril, Kenneth, Avivi, Irit, Liberati, Anna M., Minnema, Monique C., Einsele, Hermann, Lonial, Sagar, Berg, Deborah, Lin, Jianchang, Gupta, Neeraj, Esseltine, Dixie‐Lee, Richardson, Paul G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Haematological Malignancy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5574012/
https://www.ncbi.nlm.nih.gov/pubmed/28485007
http://dx.doi.org/10.1111/bjh.14733

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5574012/
https://www.ncbi.nlm.nih.gov/pubmed/28485007
http://dx.doi.org/10.1111/bjh.14733

Ejemplares similares